Viking Therapeutics (VKTX) Hits New 1-Year High at $7.18

Viking Therapeutics Inc (NASDAQ:VKTX) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $7.18 and last traded at $6.82, with a volume of 2262200 shares. The stock had previously closed at $6.82.

VKTX has been the topic of a number of research reports. Maxim Group set a $8.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. BidaskClub upgraded shares of Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 7th. ValuEngine lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Roth Capital initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, November 21st. They issued a “buy” rating and a $5.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.00.

The firm has a market capitalization of $302.99, a PE ratio of -8.45 and a beta of 2.26.

Large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of Viking Therapeutics in the 3rd quarter valued at approximately $108,000. Virtu KCG Holdings LLC purchased a new stake in shares of Viking Therapeutics in the 2nd quarter valued at approximately $124,000. Creative Planning increased its position in shares of Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 60,000 shares during the last quarter. Cornerstone Capital Inc. purchased a new stake in shares of Viking Therapeutics in the 4th quarter valued at approximately $352,000. Finally, Geode Capital Management LLC increased its position in shares of Viking Therapeutics by 276.2% in the 4th quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company’s stock valued at $477,000 after purchasing an additional 86,355 shares during the last quarter. 11.72% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://weekherald.com/2018/02/22/viking-therapeutics-vktx-hits-new-1-year-high-at-7-18.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply